This study investigated the safety of administering CTLA-4 and PD-1 immunotherapy in combination with cryoablation or standard care in patients with HER2-negative advanced breast cancer following neoadjuvant chemotherapy. This evidence concerns the gene CTLA4 and breast carcinoma.